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Aims. -e Cardiac Resynchronization -erapy (CRT) Survey II was conducted between October 2015 and December 2016 and
included data from 11088 CRT implantations from 42 countries. -e survey’s aim was to report on current European CRT
practice. -e aim of this study was to compare the Croatian national CRTpractice with the European data.Methods. Five centres
from Croatia recruited consecutive patients, in a 15-month period, who underwent CRT implantation, primary or an upgrade.
Data were collected prospectively by using online database. Results. A total of 115 patients were included in Croatia, which is
33.2% of all CRT implants in Croatia during the study period (total n � 346). Median age of the study population was 67 (61–73)
years, and 21.2% were women. Primary heart failure (HF) aetiology was nonischemic in 61.1% of patients, and HF with wide QRS
was the most common indication for the implantation (73.5%). 80% of patients had complete left bundle branch block, and over
two-third had QRS ≥150ms. Device-related adverse events were recorded in 4.3% of patients. When compared with European
countries, Croatian patients were signiﬁcantly younger (67 vs. 70 years, p � 0.012), had similar rate of comorbidities with the
exception of higher prevalence of hypertension. Croatian patients signiﬁcantly more often received CRT-pacemaker when
compared with European population (58.3 vs. 29.9%, OR 3.27, 95%CI 2.25–4.74, p< 0.001). Conclusion. Our data indicate strict
selection of patients among HF population and adherence to guidelines with exception of higher proportion of CRT-pacemaker
implantation. -is is likely to be inﬂuenced by healthcare organization and reimbursement issues in Croatia.
1. Introduction
-e advantages of cardiac resynchronization therapy (CRT)
on long-term clinical treatment of symptomatic heart failure
(HF) patients (NYHA II-IV) with reduced left ventricular
ejection fraction (LVEF) and ventricular dyssynchrony
have been constantly conﬁrmed [1–3]. Surveys and regis-
tries include all eligible consecutive patients, providing
very useful “real-world” clinical data [1, 2]. -ese data
complement the results from randomized clinical trials
(RCT), in which high-risk patients are usually not included
[2–5]. -e ﬁrst European Cardiac Resynchronization
-erapy (CRT) Survey was conducted in 2008, as a joint
project of the Heart Failure Association (HFA) and the
European Heart Rhythm Association (EHRA) of the Eu-
ropean Society of Cardiology (ESC) [6]. It was a 6-month
snapshot survey which included more than 2400 patients
with CRT implantation from 13 ESC member countries. It
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gave valuable insights into CRT clinical practice and em-
phasized underutilization of resynchronization therapy at
that time, also showing that large numbers of CRTs were
implanted not applying the guidelines recommendations [6].
In 2013 and 2016, ESC issued new guidelines on cardiac
pacing and CRT as well as on acute and chronic HF
management [7, 8]. European CRT Survey II was designed
and implemented on the basis of ﬁrst CRT Survey, but did
not include any follow-up [9]. It included 42 ESC member
countries with the aim to gather demographic and clinical
data on the HF patient selection, CRT implantation, and
follow-up practice. -is survey provided information rele-
vant for assessing healthcare resource utilization, the impact
of new guidelines on daily clinical practice, and adherence to
CRT guidelines [10]. -e aim of this study is to report
Croatian national data on resynchronization therapy
practice and compare it with the rest of the European data
gathered in the same multicentre CRT II Survey.
2. Materials and Methods
-e CRT II Survey was designed and conducted as a joint
project of the EHRA and HFA, and its design and rationale
have been published previously [9]. Between October 2015
and December 2016, all consecutive patients that underwent
a primary CRT implantation or an upgrade to a CRT-system
were eligible for inclusion, regardless of the success of the
procedure. Data were collected prospectively by using online
database. A central database was created and maintained at
the data management centre (IFH, Heidelberg University,
Germany), which also performed the data analyses. -e
overall results of the CRT Survey II were recently published
[10]. Five Croatian centres participated in the survey (out of
8 implanting CRT devices): University Hospital Centre
Rijeka, University Hospital Centre Sestre milosrdnice, Uni-
versity Hospital Centre Zagreb, University Hospital Centre
Split, and County Hospital Zadar.
-e European CRT Survey II included two internet-
based questionnaires [8, 9]. -e ﬁrst one was the ques-
tionnaire completed by a recruiting centre and included
description of hospital type, reference area size, invasive
procedures and device implantations details, cardiac facil-
ities, types of imaging equipment employed, the number and
speciality of implanting physicians, and the follow-up op-
tions provided, and ultimately the type and source of
hospital reimbursement. -e second questionnaire was an
electronic case report form (eCRF) for each patient included
in the survey. It was initiated prior to implantation, and
included patient’s demographic and clinical data, as well as
procedural and short-term postprocedural details.
Ethics approval from the relevant Ethics Committee in
Croatia was obtained. -is study was conducted according
to the Declaration of Helsinki.
2.1. Statistical Analysis. Continuous variables were pre-
sented as median with interquartile range or means with
standard deviations. Continuous variables were compared
with nonparametric Mann–Whitney U test. Categorical
variables were presented as absolute values and/or per-
centages and were compared using Pearson’s χ2 test. De-
scriptive statistics were calculated for the available cases.
Two-sided p value of < 0.05 was considered signiﬁcant.
Statistical analysis was carried out using SASã statistical
software, version 9.1 (Cary, North Carolina, USA).
3. Results
During the 15-month enrolment period (October 2015–
December 2016), a total of 115 patients (1.03%) were
recruited in Croatia, out of 11088 recruited by 288 centres in
42 ESC member countries participating in the CRT II
Survey. -is was 33.2% of all CRT implantations in Croatia
during this period (total number � 346) [11, 12].
3.1. Preprocedural Data. -e median age of Croatian CRT
population was 67 (IQR 61–73) years, and 21.2% were
women. Mean body mass index (BMI) was 27.0 ± 5.3 kg/m2,
and 22.1% of patients had normal body weight (BMI 18–
25 kg/m2). 75.2% of patients had hypertension, almost one-
third had diabetes mellitus, and 26.5% had chronic kidney
disease. 46% of patients were hospitalized due to heart
failure (HF) during the past year before the implantation. No
patient was asymptomatic or classiﬁed as NYHA functional
class I, whereas 48.2% were in class II, 50% in class III, and
1.8% in NYHA class IV (Table 1). Primary HF aetiology was
nonischemic in 61.1% of included patients. Concerning
baseline heart rhythm and ECG, 23% of patients were in
atrial ﬁbrillation at the time of implantation, and 15% had
AV II/III degree block. 80% of patients had complete left
bundle branch block (LBBB), over two-third had QRS≥150ms, and 8.3% had QRS <120ms. Heart failure with
wide QRS complex was the most common indication for
CRT implantation by far (73.5% of cases) followed by LV
dysfunction with an indication for an implantable
cardioverter-deﬁbrillator (ICD) (27.4%) (Table 1).
-e mean NT-pro BNP value was 3447.5 ±
3270.8 pg/mL; however, it was assessed in only 15.6% of
patients. According to echocardiography, mean LVEDDwas
65.6 ± 8.5mm, mean was LVEF 29.1 ± 7.3% with 25.6% of
patients having LVEF > 35%, and no patient had LVEF >
50%. 87.1% of patients had some degree of mitral re-
gurgitation, mostly moderate (50%).
3.2. Procedural Data. -e CRT-P device was implanted in
58.3% and CRT-D in 41.7% of patients. -e procedure was
done by an electrophysiologist in 88.7% of cases, and mostly
performed in the catheterization laboratory (55.7%). -e
median duration of the procedure was 100min (IQR 80–
120) with a median ﬂuoroscopy time of 15min (IQR 10–22).
92.2% of patients received prophylactic antibiotics pre-
procedurally. Positioning of the leads was reported by the
operator. -e right ventricular (RV) lead was almost always
placed before the left ventricular (LV) lead (98.3% of cases)
and was most often positioned in the RV apex (75.4%). -e
LV lead was placed in the lateral position in 92.2%, and in the
posterior position in 7% of patients. Operators mostly used
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Table 1: Baseline characteristics and preprocedural data of Croatian CRT population and comparison with the European population.
Croatia Europe p value OR (95% CI)
Demographics
Age 66.1 ± 11.0 68.6 ± 10.8 0.017
Men 78.8 (89/113) 75.7 (8277/10939) 0.445
BMI 28.1 ± 4.2 27.9 ± 5.0 0.162
History
Hypertension 75.2 (85/113) 63.8 (6877/10787) 0.012 1.73 (1.12–2.65)
Diabetes mellitus 30.1 (34/113) 31.4 (3394/10808) 0.765
Obstructive lung disease 8.8 (10/113) 12.1 (1305/10809) 0.295
Atrial ﬁbrillation 33.6 (38/113) 40.9 (4421/10807) 0.117
Paroxysmal 28.9 (11/38) 34.8 (1537/4421) 0.344
Persistent 21.1 (8/38) 22.3 (986/4421)
Permanent 50.0 (19/38) 42.3 (1870/4421)
Chronic kidney disease (<60) 26.5 (30/113) 31.2 (3365/10794) 0.291
Prior revascularization (CABG or PCI) 50.4 (57/113) 75.3 (8145/10813) 0.006 0.56 (0.36–0.86)
HF hospitalisation during last year 46.0 (52/113) 46.5 (5026/10804) 0.915
Prior device (PPM, ICD) 13.3 (15/113) 28.0 (3044/10879) <0.001 0.39 (0.23–0.68)
Primary HF aetiology 0.477
Ischaemic 38.1 (43/113) 44.6 (4832/10840)
Nonischaemic 61.1 (69/113) 49.7 (5384/10840)
Others 0.9 (1/113) 5.8 (624/10840)
ECG
Heart rate (beats/min) 76 ± 19 72 ± 16 0.028
Sinus rhythm 76.1 (86/113) 69.1 (7410/10723) 0.071
Atrial ﬁbrillation 23.0 (26/113) 25.7 (2752/10723)
PR interval (ms) 182 ± 47 189 ± 50 0.337
AV block II or III 15.0 (17/113) 19.0 (2009/10587) 0.289
QRS duration (ms) 154 ± 24 157 ± 27 0.436
QRS duration <120ms 8.3 (9/108) 7.4 (702/9427)
QRS duration 120–130ms 5.6 (6/108) 5.3 (499/9427)
QRS duration 130–150ms 18.5 (20/108) 18.7 (1759/9427)
QRS duration 150–180ms 48.1 (52/108) 47.0 (4434/9427)
QRS duration >180ms 19.4 (21/108) 21.6 (2033/9427)
QRS morphology
LBBB 80.0 (88/110) 75.2 (7750/10307) 0.245
RBBB 8.2 (9/110) 6.6 (679/10307) 0.503
Others 11.8 (13/110) 18.2 (1878/10307) 0.083
CRT indication
Heart failure with wide QRS 73.5 (83/113) 59.8 (6467/10810) 0.003 1.86 (1.22–2.83)
HF or LV dysfunction and an indication for ICD 27.4 (31/113) 48.1 (5197/10810) 0.001 0.41 (0.27–0.62)
PM indication + expected pacing dependency 21.2 (24/113) 22.8 (2470/10810) 0.685
Evidence of medical dyssynchrony 4.4 (5/113) 11.6 (1255/10810) 0.018 0.35 (0.14–0.87)
Clinical evaluation 0.158
NYHA I 0.0 (0/112) 3.4 (370/10736)
NYHA II 48.2 (54/112) 37.5 (4029/10736)
NYHA III 50.0 (56/112) 54.5 (5853/10736)
NYHA IV 1.8 (2/112) 4.5 (484/10736)
Echocardiography
Mean LV ejection fraction (%) 29.1 ± 7.3 28.4 ± 8.2 0.314<35% 74.3 (84/113) 76.6 (8198/10692)
35–50% 25.6 (29/113) 21.5 (2299/10692)>50% 0.0 (0/113) 1.8 (195/10692)
LV end-diastolic diameter (mm) 65.6 ± 8.5 63.5 ± 9.1 0.039
Mitral regurgitation <0.001
Mild 39.2 (40/102) 46.5 (4604/9898) 0.74 (0.50–1.11)
Moderate 50.0 (51/102) 26.2 (2595/9898) 2.81 (1.90–4.16)
Severe 7.8 (8/102) 6.9 (682/9898) 1.15 (0.56–2.38)
None 2.9 (3/102) 20.4 (2017/9898) 0.12 (0.04–0.37)
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the bipolar LV lead (95.7%) and the multipolar lead in 4.3%
of cases. Regarding the procedural complications, no patient
died during the implantation. -ere were no bleeding
complications, 5 patients had coronary sinus dissections
(4.3%), and 1 patient had pneumothorax (0.9%). Detailed
procedural data are given in Table 2.
3.3. Postprocedural Data. -e mean length of hospital stay
was 6.8 ± 7.5 days. 1 patient died during hospitalization
following the implantation due to noncardiovascular rea-
sons. Device-related adverse events after the implantation
were recorded in 4.3% of patients. Lead displacement was
observed in 2.7%, dominantly on behalf of the LV lead
Table 1: Continued.
Croatia Europe p value OR (95% CI)
Laboratory results
NT-pro BNP (pg/mL) 3447.5 ± 3270.8∗ 5111.8 ± 8144.1 0.725
Hemoglobin (g/L) 13.6 ± 1.6 13.3 ± 1.8 0.079
Creatinine (μmol/L) 107.1 ± 36.7 114.1 ± 65.9 0.417
Values are % (n) for categorical and mean ± standard deviation or median (25th–75th percentile) for continuous variables. BMI: body mass index; CABG:
coronary artery bypass grafting; PCI: percutaneous coronary intervention; HF: heart failure; PPM: permanent pacemaker; ICD: implantable cardioverter-
deﬁbrillator; LBBB: left bundle branch block; RBBB: right bundle branch block; LV: left ventricle; BNP: brain-type natriuretic peptide. ∗NT-pro BNP was
measured only in 18 patients in Croatia (15.6% of patients).
Table 2: Procedural data of Croatian CRT population and comparison with the European practice.
Croatia Europe p value OR (95% CI)
Elective procedure 85.1 (97/114) 76.9 (8325/10832) 0.038 1.72 (1.02–2.88)
Location of procedure <0.001
Cath lab 55.7 (64/115) 24.9 (2654/10643) 3.78 (2.61–5.47)
Dedicated EP lab 20.0 (23/115) 30.8 (3277/10643) 0.56 (0.36–0.89)
Device implantation lab 22.6 (26/115) 33.6 (3575/10643) 0.58 (0.37–0.90)
Operating theatre 1.7 (2/115) 10.2 (1082/10643) 0.16 (0.04–0.63)
Operator 0.014
Electrophysiologist 88.7 (102/115) 76.9 (8200/10664) 2.36 (1.32–4.21)
Heart failure physician 0.0 (0/115) 5.1 (541/10664) /
Invasive cardiologist 1.7 (2/115) 12.5 (1328/10664) 0.12 (0.03–0.50)
Surgeon 0.9 (1/115) 4.3 (463/10664) 0.19 (0.03–1.39)
Others 8.7 (10/115) 1.2 (132/10664) 7.6 (3.88–14.86)
Duration of procedure (min) 100 (80, 120) 90 (65, 120) 0.163
Fluoroscopy time (min) 15 (10, 22) 14 (8, 22) 0.11
RV lead position 0.002
Apex 75.4 (86/114) 61.1 (6194/10139) 1.96 (1.27–3.00)
Septum 23.7 (27/114) 36.6 (3706/10139) 0.54 (0.35–0.83)
RVOT 0.9 (1/114) 2.4 (239/10139) 0.37 (0.05–2.64)
LV lead position 0.7
Anterior 0.9 (1/115) 4.4 (446/10185) 0.19 (0.03–1.37)
Lateral 92.2 (106/115) 84.0 (8559/10185) 2.24 (1.13–4.43)
Posterior 7.0 (8/115) 11.6 (1180/10185) 0.57 (0.28–1.17)
LV lead type <0.001
Unipolar 0.0 (0/115) 0.7 (77/10486) /
Bipolar 95.7 (110/115) 41.7 (4368/10486) 30.81 (12.5–75.5)
Multipolar 4.3 (5/115) 57.6 (6041/10486) 0.03 (0.01–0.08)
Coronary venogram performed 99.1 (114/115) 91.4 (9522/10414) 0.003 10.68 (1.49–76.5)
Venogram with occlusion 62.3 (71/114) 46.9 (4415/9408) 0.001 1.87 (1.28–2.73)
Test shock 0.9 (1/115) 4.8 (505/10531) 0.049 0.17 (0.02–1.25)
Periprocedural complications 5.2 (6/115) 5.6 (618/10973) 0.848
Bleeding 0.0 (0/115) 1.0 (108/10973) 0.772
Pocket haematoma 0.0 (0/115) 0.8 (85/10973) 0.285
Pneumothorax 0.9 (1/115) 1.0 (111/10973) 0.879
Pericardial tamponade 0.0 (0/115) 0.3 (28/10973) 0.587
Coronary sinus dissection 4.3 (5/115) 1.9 (209/10973) 0.058
Type of the device (%) <0.001
CRT-P 58.3 (67/115) 29.9 (3189/10654) 3.27 (2.25–4.74)
CRT-D 41.7 (48/115) 70.1 (7465/10654) 0.31 (0.21–0.44)
Prophylactic antibiotics 92.2 (106/115) 98.7 (10421/10557) <0.001 0.15 (0.08–0.31)
Values are % (n) for categorical and mean ± standard deviation or median (25th–75th percentile) for continuous variables. EP: electrophysiology; RV: right
ventricle; RVOT: RV outﬂow tract; LV: left ventricle; CRT-P: cardiac resynchronization therapy pacemaker system; CRT-D: cardiac resynchronization
therapy cardioverter-deﬁbrillator system.
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(66.7%) (Table 3). Phrenic nerve stimulation was observed in
2 patients, but it did not require a new procedure. -ere was
no infection related to the CRT implantation during the
hospitalization. -e mean paced QRS duration after opti-
mization was 113± 19ms. Detailed data on medication
therapy at discharge are given in Table 3. Follow-up was
planned for every patient only at the implanting centre.
3.4. Comparison with European Practice. When compared
with other European countries (total of 10973 patients),
Croatian CRT population (n � 115) was signiﬁcantly
younger (67 vs. 70 years, p � 0.012), had lower proportion of
patients > 75 years (22.1 vs. 32.1%, OR 0.6, 95%CI 0.38–0.94,
p< 0.001), and had similar low implantation rate in women
(21.2 vs. 24.3%, p � 0.445). Baseline and preprocedural data
of both groups are given in Table 1. Regarding comorbidities,
Croatian patients had higher prevalence of arterial hyper-
tension (OR 1.73, 95%CI 1.12–2.65, p � 0.012) and lower
prevalence of previous coronary revascularization (OR 0.56,
95%CI 0.36–0.86, p � 0.006) and previously implanted
devices (OR 0.39, 95%CI 0.23–0.68, p< 0.001). Regarding the
NYHA functional class, there was no signiﬁcant diﬀerence
overall. HF with wide QRS as the main indication for CRT
implantation was signiﬁcantly more often in Croatian patients
(OR 1.86, 95%CI 1.22–2.83, p � 0.003). Croatian patients had
similar rate of LVEF <35%, complete LBBB, and QRS< 150ms
in comparison with average European population. According
to echocardiography, mean LVEF was similar between the
groups, even when divided in groups: on <35%, 35–50%, and>50%. However, Croatian patients had higher LV end-diastolic
diameter (65.6 vs. 63.5mm, p � 0.039) and higher prevalence
Table 3: Postprocedural data of Croatian CRT population and comparison with the European average.
Croatia Europe p value OR (95% CI)
Hospital mortality 0.9 (1/111) 0.4 (44/10734) 0.409
Device-related complications
Lead displacement 2.7 (3/110) 1.7 (185/10720) 0.424
RV 0.0 (0/3) 31.6 (55/174) 0.241
LV 66.7 (2/3) 52.3 (91/174) 0.621
Atrial 33.3 (1/3) 19.0 (33/174) 0.531
Lead malfunction 0.0 (0/110) 0.2 (23/10720) 0.627
Phrenic nerve stimulation 1.8 (2/110) 1.1 (121/10720) 0.497
Infection 0.0 (0/110) 0.6 (60/10706) 0.431
Stroke 0.0 (0/110) 0.1 (6/10706) 0.804
Worsening of HF 0.0 (0/110) 0.7 (78/10706) 0.369
Arrhythmias 0.9 (1/110) 1.2 (127/10706) 0.789
Total length of hospital stay 6.8 ± 7.5 6.3 ± 11.4 0.002
Mean-paced QRS duration (ms) 113 ± 19 138 ± 24 <0.001
Medical therapy at discharge
Diuretic 89.1 (98/110) 81.0 (8523/10525) 0.031 1.92 (1.05–3.50)
ACE inhibitor/ARB 84.1 (90/107) 86.4 (9073/10496) 0.484
Aldosterone antagonist 71.8 (79/110) 63.1 (6603/10463) 0.059
Beta blocker 94.5 (104/110) 88.9 (9368/10538) 0.06
Digoxin 5.6 (6/107) 10.5 (1094/10437) 0.101
Calcium channel blocker 6.7 (7/105) 9.0 (939/10426) 0.404
Amiodarone 35.5 (38/107) 17.1 (1787/10440) <0.001 2.67 (1.79–3.98)
Ivabradine 0.0 (0/108) 5.7 (593/10435) 0.011 /
Other antiarrhythmic agents 1.9 (2/108) 1.7 (179/10423) 0.256
Oral anticoagulant 46.4 (51/110) 46.6 (4877/10467) 0.962
Vitamin K antagonist 86.3 (44/51) 70.1 (3419/4877) 0.012 2.68 (1.20–5.96)
Dabigatran 3.9 (2/51) 6.7 (325/4877) 0.434
Rivaroxaban 3.9 (2/51) 12.5 (609/4877) 0.065
Apixaban 5.9 (3/51) 10.4 (506/4877) 0.294
Edoxaban 0.0 (0/51) 0.4 (18/4877) 0.664
Platelet inhibitor 25.2 (29/115) 43.9 (4817/10973) <0.001 0.43 (0.28–0.66)
ASA 24.8 (27/109) 41.5 (4330/10438) <0.001 0.46 (0.30–0.72)
Clopidogrel 6.4 (7/109) 12.4 (1297/10438) 0.058 0.48 (0.22–1.04)
Ticagrelor 0.9 (1/109) 1.3 (135/10438) 0.729 0.71 (0.10–5.10)
Dual antiplatelet therapy 5.5 (6/109) 9.3 (975/10438) 0.17
OAC plus P2Y12 inhibitor 1.8 (2/110) 4.2 (438/10510) 0.219
Triple therapy 1.8 (2/110) 2.1 (216/10511) 0.862
Device follow-up planned 95.7 (110/115) 97.6 (10708/10973) 0.181 0.54 (0.22–1.35)
At implanting centre 100.0 (110/110) 86.2 (9235/10708) <0.001
Values are % (n) for categorical and mean ± standard deviation or median (25th–75th percentile) for continuous variables. RV: right ventricle; LV: left
ventricle; ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blocker; ASA: acetylsalicylic acid; OAC: oral anticoagulation.
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of moderate mitral regurgitation (OR 2.81, 95%CI 1.90–4.16,
p< 0.001).
-e comparison of procedural data between the groups is
given in Table 2. Croatian patients were signiﬁcantly more
likely to receive CRT-P device when compared with European
average (58.3 vs. 29.9%, OR 3.27, 95%CI 2.25–4.74, p< 0.001).
-ere were signiﬁcantly less upgrade procedures to CRT
system (13.3 vs. 28%, OR 0.39 (0.23–0.68, p< 0.001). In
Croatia, the implantation procedure was more often elective
(OR 1.72, 95%CI 1.02–2.88, p � 0.037), done more often by
an electrophysiologist (OR 2.36, 95%CI 1.32–4.21, p � 0.014)
and almost 4 times more likely to be done in a catheterization
laboratory (OR 3.78, 95%CI 2.61–5.47, p< 0.001). -ere was
no diﬀerence regarding both the total duration of the pro-
cedure and ﬂuoroscopy time between the groups. In Croatia,
the multipolar LV lead was used signiﬁcantly less often (OR
0.03, 95%CI 0.01–0.08, p< 0.001), but during coronary sinus
venogram, the usage of balloon occlusion was almost 2-fold
more common (OR 1.87, 95%CI 1.28–2.73, p � 0.001). De-
ﬁbrillation threshold testing was carried out less often (0.9 vs.
4.8%, OR 0.17, 95%CI 0.02–1.25, p � 0.049). Regarding
procedural complications, there were no signiﬁcant diﬀer-
ences between the groups (p � 0.847). Total length of hospital
stay was longer in Croatia (6.8 vs. 6.3 days, p � 0.002).
Postprocedurally, the duration of QRS after optimization was
signiﬁcantly lower in Croatian patients (113 vs. 138ms,
p< 0.001). -ere were no diﬀerences regarding the incidence
of major adverse events connected to implantation during the
hospitalization. -ere was a statistically signiﬁcant diﬀerence
between the groups regarding the discharge medication
therapy and the follow-up planning. -e complete post-
procedural data are given in Table 3.
4. Discussion
European CRT Survey II was a 15-month snapshot survey,
carried out by EHRA and HFA, and it provides a robust
overview of the current clinical practice and guideline ad-
herence regarding CRT across a wide range of centres in 42
ESC member countries [9, 10]. Croatia is a small country
with around 4.5 million inhabitants and a gross domestic
product (GDP) of 11’858 USD, and it allocates 7.8% of its
GDP for healthcare [12]. In the last decade, a signiﬁcant
increase in CRT implantation number has been recorded.
For comparison, in 2008 when CRT Survey I was conducted,
only 5 CRTs per million inhabitants were implanted in
Croatia, while in 2016, that number grew to 64, which is an
increase of more than 900%, but still low when compared
with Western European countries (Figure 1) [11, 12]. 5 out
of 8 centres that implant CRT participated in the CRT II
Survey. -ey are all classiﬁed as medium or high volume
centres, and they did 88.5% of all CRTs implantation in 2016
[11]. However, only 33.2% of all implanted cases in the study
period were reported, which could have biased the national
results [11, 13]. -is is also true for other countries par-
ticipating in the survey. -erefore, comparison between
Croatia and Europe could be accurate; however, Croatian
results could have been slightly diﬀerent if all patients from
all implanting centres were included.
-e data show that Croatian patients were signiﬁcantly
younger when compared with the average European
population, however with rather high prevalence of
comorbidities, especially of hypertension which is in line
with previous epidemiological studies of general pop-
ulation in Croatia [14]. A consistent ﬁnding was the low
proportion of women receiving CRTs both in Croatia and
across Europe, even though women have better survival
after CRT implantation [1, 6, 8, 10, 15]. Croatian patients
had more elective hospitalization for CRT implantation
(85%), although almost half of the patients (46%) were
hospitalized due to HF during the past year before the
implantation. -is is probably due to organizational ar-
rangements concerning hospitals’ budget limitations and
reimbursement issues and a need to screen the population
with the CRT indication [10, 12, 16, 17]. Also, patients in
Croatia received more CRT-pacemaker (CRT-P) devices
compared with other European countries (58 vs. 30%)
despite a signiﬁcant proportion having an indication for
a CRT-deﬁbrillator according to the current guidelines [7].
We can speculate that this is mainly due to healthcare
organization, reimbursement, and budget restrictions
[17–19]. However, this is in compliance with the new
cohort studies and meta-analysis on sudden cardiac death
(SCD) in HF population, which stress the importance of
pharmacological therapy and CRT-P in SCD prevention
[20–22]. Even stricter adherence to guidelines is notable
when the patient selection is closely studied: majority have
nonischemic aetiology of HF, 80% complete LBBB, two-
third QRS >150ms, and less than 25% were > 75 years old.
All aforementioned are the signiﬁcant predictors of good
CRT response and better long-term clinical outcome
[1–3, 6–8, 20–22]. -is kind of selection from HF pop-
ulation with a CRT indication is presumably caused by
limited budget. Likewise, mostly bipolar electrodes were
implanted, and more often in comparison with other
European countries, even though quadripolar leads are
more cost-eﬀective in the long term [23].
In Croatia, although procedures did not last signiﬁcantly
longer than the European average, most patients had the LV
lead positioned laterally, which is the golden standard, but
not easily achievable [1–3, 24, 25]. Moreover, this could
0
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Figure 1: Number of CRT implantations per million inhabitants in
Croatia in the last decade.
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explain the very narrow postprocedural QRS in Croatian
patients, signiﬁcantly narrower in comparison with the
European counterparts, which is a predictor of clinical
outcome, but could also explain higher incidence of coro-
nary sinus dissection [2, 3, 22–25]. Procedures were mostly
done in the catheterization laboratory, probably inﬂuenced
by organizational characteristics of implanting centres.
However, since these centres do most of CRT implantation
in Croatia, it was expected for them to be provided in
a specialized electrophysiology implanting room. Also, most
of the procedures were done by electrophysiologist, which is
expected due to complexity of the procedure and the total
number of CRTs implanted through the year [11–13]. Over
the years, the number of all cardiac devices implanted by
surgeons has decreased signiﬁcantly in Croatia [11, 13].
-e reported perioperative complication rate was low,
which is in line with the fact that centres that participated are
medium or high volume centres [12, 26, 27]. -e Croatian
group had no bleeding complications, which are the most
common, and which is in line with the lower rate of patients
on antiplatelet and/or anticoagulant therapy [7, 26–28].
Regarding the discharge medication therapy, Croatian
patients were signiﬁcantly more often prescribed with
Warfarin as anticoagulation therapy, since novel antico-
agulants (NOAC) are only partially covered by the public
health insurance [18, 19, 29].
-e Croatian CRT population when compared with
the average European population was signiﬁcantly
younger and had similar rate of comorbidities and even
higher rate of hypertension. More than 30% of all CRT
implants during the study period were included in this
survey, which makes the data highly representative for
Croatia. Most of the patients that received CRT had one
or more signiﬁcant predictors of good clinical outcome:
complete LBBB, HF with wide QRS as a main indication,
QRS > 150ms, nonischemic aetiology of cardiomyopa-
thy, and younger than 75 years. Like in the overall survey,
many but not all CRT implantations were made in ac-
cordance with Guidelines indication IA [10]. -e overall
Croatian implantation practice showed high adherence
to current guidelines which was similar to European
practice, which is not the case in the CRT Survey I [2, 10].
Also, the CRT-pacemaker system was implanted in
signiﬁcantly higher proportion. -ere are probably
several reasons for that. First, budget limitations sig-
niﬁcantly limit the number of more expensive CRT-D
devices, which partially explains this diﬀerence [17–19].
Second, such patients beneﬁt the most from CRT which
modiﬁes the HF condition and have less added beneﬁt
from adding ICD to CRT [20, 21]. -is selectiveness of
physicians when choosing patients for CRT implantation
among HF population is also probably driven by budget
limitations [17–19, 29].
In conclusion, Croatian national data from the Eu-
ropean CRT Survey II provides clinicians and healthcare
providers with data useful for improving HF patient
management and could drive our eﬀorts for better re-
imbursement policy with the goal of providing CRT
therapy to a higher number of patients.
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